KIMOVI Cream for Dry, Irritated & Sensitive Skin - 150ml

KIMOVI Cream for Dry, Irritated & Sensitive Skin - 150ml

  • Versatile, mild & soothing cream for dry, irritated skin
  • Contains ingredients proven to help restore skin
  • Suitable for children
£ 4.99 £ 19.99
  • Products sold at our cost price
  • Add up to 6 products
  • UK Shipping at just £4.99
  • Limited international shipping available

KIMOVI Cream is a mild and soothing treatment designed to ease the symptoms of dry and sensitive skin. This includes skin that is red and irritated, and skin that has been damaged by the sun.

It is considered mild because it is free of the fragrances, colorants, and parabens that are often found in skincare treatments. These can irritate sensitive skin or skin affected by a condition, often worsening its health and appearance.

Now available in the UK, KIMOVI Cream contains two ingredients from Africa in particular that are well associated with restoring skin: Shea Butter and Kigelia Africana.

The latter is derived from a tropical African fruit tree and is well-known for its skin restoring qualities. Shea Butter is an ivory-colored fat from the nut of the shea tree. It is often used in high quality cosmetics because of its benefits as a moisturiser.

Combining these two effective ingredients, this cream can help to provide lasting healing and relief to people suffering from minor skin irritations. According to KIMOVI Cream reviews, it is easily absorbed by the skin, with a moisturising action that helps to soothe dry skin and soften it. With regular use especially, the condition of the skin can be expected to improve.

Unlike other creams and gels in the KIMOVI collection of products, this cream contains no thermal mineral salts. It is well tolerated and suitable for both adults and children to use daily.


See active ingredients for: .

We didn't find any ingredients for the product.


KIMOVI Cream can be used as a daily moisturising treatment on the body and face. While it is suitable for use by children and adults, please understand the precautions listed below.

It can be used on its own or in combination with other skin treatments.


KIMOVI Cream is considered safe to use but keep away from the eyes and store it away from the sight and reach of children.

If there is contact with the eyes, flush the cream out with clean water.

This product contains a relatively long list of ingredients, Check it for allergies before using this cream. If you experience an adverse skin reaction, stop using the cream and speak to a medical professional if symptoms persist.

Side Effects

KIMOVI Cream has no reported side effects. There are no known interactions with other medicinal products.

Scientific Research

For people with Psoriasis

HelloSkin’s experts were unable to find clinical data on the use of KIMOVI cream in people with psoriasis or other dry skin conditions.

The product contains glycerin and shea butter. Glycerin is a part of the natural moisturising factor in the skin, helping to hydrate and moisturise the skin (1). Water evaporation is increased in psoriatic lesions in comparison to in normal skin (2), which is linked to a reduced skin barrier function and can aggravate disease symptoms (3).

KIMOVI cream also contains fruit extract from the African plant, Kigelia Africana. Kigelia Africana is reported to be widely used as a natural treatment (4) and although many of its traditional medicinal uses have not been investigated scientifically, it is presumed to have antimicrobial, antioxidant and wound healing properties. One of its suggested bioactive substances is verminoside, which has been reported to have anti-inflammatory properties in immune cells, in laboratory models (5).

Laboratory studies have also shown Kigelia africana extracts to have antibacterial activities against a range of test bacteria including Staphylococcus aureus (6). In psoriatic plaques, colonisation with the bacteria S. aureus may be increased (7). One study reported that S. aureus was present in 15 of 25 of the psoriatic plaques that were investigated of which one third of the bacteria was toxigenic, and that the disease severity was linked to a higher enterotoxin production (8).


  1. Dermatol Ther. 2004;17 Suppl 1:49-56
  2. Ann Dermatol. 2012 May;24(2):168-74
  3. Am J Clin Dermatol. 2003;4(11):771-88
  4. J Ethnopharmacol. 2016 Aug 2;189:253-76
  5. J Nat Prod. 2005 Nov;68(11):1610-4
  6. Adv Pharmacol Sci. 2013;2013:692613
  7. Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1069-77
  8. J Am Acad Dermatol. 2005 Jul;53(1):67-72
- was added to your cart.